The global kidney function tests market size was valued at USD 1.2 billion in 2016 and is expected to grow at a CAGR of 5.2% over the forecast period. The growing prevalence of chronic kidney diseases is presumed to be responsible for growth attained by this market. The high prevalence is predominantly believed to be a consequence of adoption of unhealthy lifestyle across the globe. This has triggered clinicians to use renal function tests on a large scale to aid in diagnosis. Consequently, the high need for efficient diagnostics, such as renal function tests, has resulted in an unprecedented market growth.
Technological advancements in renal function tests have led to early disease identification and specialized diagnosis of certain conditions on a larger scale. These advancements include advanced parameter estimation, computer-assisted interpretation, and usage of automated analyzers.
North America kidney function tests market, by product, 2014 - 2025 (USD Million)
The benefits of above mentioned advancements are greater process control, allowing real-time automation; automatic variable adjustment; and efficient parameter monitoring. These tools also offer analysis of a wide array of samples and provide rapid results, reflecting their potential application in hospitals, outpatient clinics, and emergency wards in future. These benefits are estimated to drive physician preference for these tests, thus creating high-potential opportunities for growth during the forecast period.
In addition, initiatives and recommendations, to achieve efficient chronic kidney disease management, by public & private healthcare organizations are on the rise. For instance, the CDC has launched Chronic Kidney Disease (CKD) Initiative that works in direction of promoting awareness and developing comprehensive public strategies to curb the rising CKD incidence. This initiative encourages clinicians to use early diagnostic methods, such as kidney function panel, which serve as one of the key growth contributing factors for the market.
Clearance tests accounted for the largest share of over 30.0% in the product segment in 2016 as a consequence of being gold standard for measurement and monitoring of glomerular filtration rate. The increased adoption rate can be attributed to the presence of a wide array of these products available in the market. These predominantly include inulin and creatinine tests that are extensively used and are considered a useful addition to conventional diagnostic procedures, in order to obtain accurate results in diagnostic procedures.
In addition, these are presumed to be highly cost efficient, possessing optimum precision and sensitivity, thereby ensuring minimum performance variation. Furthermore, growing number of collaborative agreements to develop highly advanced tests are expected to broaden the penetration rate of kidney function panel. For instance, in January 2015, bioMerieux and Astute Medical entered into a collaborative agreement to develop as well as distribute NephroCheck Test for VIDAS-an assay designed for risk assessment for acute kidney injury.
Global kidney function tests market share, by end-use, 2016 (%)
Hospitals held a substantial share of the end-use segment in 2016, which can be attributed to the frequent readmissions and high patient volume. Also, the presence of sophisticated infrastructure facilitates high efficiency in diagnostic procedures involving renal function panel, thereby adding to a higher share of hospitals.
The growing inclination of government healthcare organizations to promote the usage of advanced diagnostic methods that generate rapid results also serves as one of the key factors responsible for the substantial share registered by this segment. Furthermore, in the present scenario, hospitals increasingly use fully automated systems possessing the ability to diagnose this condition at early stages. These factors cumulatively are anticipated to exert a positive influence on the segment growth over the coming years.
In 2016, North America accounted for a substantial share of the kidney function tests market. The presence of supportive government initiatives and their consistent implementation by healthcare organizations are some of the key factors responsible for the high share captured by this region.
As a consequence of increase in the outsourcing of contracts by global level players to Asia Pacific countries, such as India and China, this region is predicted to grow at a lucrative rate during the forecast period. Furthermore, a gradual increase in R&D investment by the global players and the presence of unexplored opportunities across this region serve as high growth rendering drivers.
This industry is expected to exhibit extensive competition during the forecast period owing to rising number of collaborative strategies between the key companies in order to obtain a competitive advantage over others. The other strategies incorporated are mergers & acquisitions, high R&D investment, and agreements for new product development.
For instance, in July 2016, ARKRAY, Inc. announced the release of AUTION MAX AX-4060, designed for automated measurement of microalbumuria and proteinuria, useful in early detection of CKD. Similarly, in July 2015, IDEXX Laboratories announced the launch of kidney function test-Symmetric Dimethylarginine (SDMA) Test-designed to identify diseases in early phases of disease progression.
Attribute |
Details |
Base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Market representation |
Revenue in USD Million & CAGR from 2017 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
Country scope |
U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the kidney function tests market on the basis of product, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Dilution & Concentration Tests
Clearance Tests
Urine Tests
Imaging Tests
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals
Diagnostic Laboratories
Academic Research Laboratories
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.